Interpretation von erhöhtem Troponin bei Patienten mit ischämischem Schlaganfall

J. F. Scheitz; M. Endres; C. H. Nolte

doi:10.1055/s-0037-1616354

Nervenheilkunde, Table of Contents

Nervenheilkunde 2016; 35(02): 7-12
DOI: 10.1055/s-0037-1616354

Kompetenznetz Schlaganfall

Schattauer GmbH

Interpretation von erhöhtem Troponin bei Patienten mit ischämischem Schlaganfall

Interpretation of elevated cardiac troponins in patients with ischaemic stroke

Authors

J. F. Scheitz

¹Klinik und Hochschulambulanz für Neurologie, Charité – Universitätsmedizin Berlin

²Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin
M. Endres

¹Klinik und Hochschulambulanz für Neurologie, Charité – Universitätsmedizin Berlin

²Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin

³Excellence Cluster NeuroCure, Charité – Universitätsmedizin Berlin

⁴German Center for Neurodegenerative Diseases (DZNE), Berlin

⁵Berlin Institute of Health (BIH), Berlin
C. H. Nolte

¹Klinik und Hochschulambulanz für Neurologie, Charité – Universitätsmedizin Berlin

²Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin

Abstract

Zusammenfassung

Kardiales Troponin (cTn) ist aufgrund der hohen Sensitivität und Spezifität für Myokardschädigungen obligater Bestandteil bei der Diagnosestellung eines akuten Myokardinfarktes. Allerdings zeigt ein erhöhtes cTn nicht die Entstehungsmechanismen der Myokardschädigung an. Bereits seit vielen Jahrzehnten ist bekannt, dass es im Rahmen akuter zerebrovaskulärer Ereignisse häufig zu kardialen Komplikationen wie Arrhythmien, kardialer Dysfunktion, autonomer Imbalance, EKG-Veränderungen und zum Anstieg kardialer Biomarker kommen kann. Dies kann im Einzelfall große differenzialdiagnostische Probleme bereiten. Die weite Verbreitung hochsensitiver cTn-Assays, die sehr geringe Mengen cTn nachweisen können, hat diese Situation weiter verschärft. Ziel dieses Übersichtsartikels ist es, die Literatur hinsichtlich Häufigkeit und prognostischer Bedeutung von cTn-Erhöhungen nach Schlaganfall zusammenzufassen, Entstehungsmechanismen von cTn-Erhöhungen nach Schlaganfall zu erläutern und dem Kliniker Hinweise für die Interpretation und den Umgang mit pathologischen cTn-Werten zu geben.

Summary

Cardiac troponin (cTn) is the biomarker of choice for diagnosis of myocardial infarction. Although cTn is a highly specific biomarker for myocardial injury, it does not reveal the underlying pathomechanism. It has long been recognized that acute cerebrovascular events are often accompanied by cardiac dysfunction, autonomic imbalance, ECG alterations and elevation of cardiac bio-markers. Thus, interpretation of elevated cTn may be challenging in the individual patient. Uncertainties further increased with the wide-spread use of high-sensitivity cTn assays, which enable detection of minute amounts of myocardial injury. In this narrative review, we aim to summarize data on frequency and prognostic relevance of cTn elevation in acute ischaemic stroke, describe underlying causes of cTn elevation, and provide clinicians with tools for interpretation and reasonable application of cTn.

Schlüsselwörter

Troponin - ischämischer Schlaganfall - Prognose - Interpretation - Myokardinfarkt

Keywords

Troponin - ischemic stroke - prognosis - myocardial infarction

Full Text

References

Literatur
1 Newby LK, Jesse RL, Babb JD. et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2012; 60: 2427-63.
2 Schelbert EB, Cao JJ, Sigurdsson S. et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA 2012; 308: 890-896.
3 Thygesen K, Alpert JS, Jaffe AS. et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60: 1581-1598.
4 Wu AH. Cardiac troponin: friend of the cardiac physician, foe to the cardiac patient?. Circulation 2006; 114: 1673-1675.
5 White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis?. J Am Coll Cardiol 2011; 57: 2406-2408.
6 Katus HA, Remppis A, Looser S, Hallermeier K, Scheffold T, Kubler W. Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients. J Mol Cell Cardiol 1989; 21: 1349-1353.
7 Amsterdam EA, Wenger NK, Brindis RG. et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130 (25) 2354-2394.
8 Reichlin T, Hochholzer W, Bassetti S. et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361: 858-867.
9 Wu AH, Jaffe AS. The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. Am Heart J 2008; 155: 208-214.
10 Scheitz JF, Endres M, Mochmann HC, Audebert HJ, Nolte CH. Frequency, determinants and outcome of elevated troponin in acute ischemic stroke patients. Int J Cardiol 2012; 157: 239-342.
11 Scheitz JF, Nolte CH, Laufs U, Endres M. Application and interpretation of high-sensitivity cardiac troponin assays in patients with acute ischemic stroke. Stroke 2015; 46: 1132-1140.
12 Furtner M, Ploner T, Hammerer-Lercher A, Pechlaner R, Mair J. The high-sensitivity cardiac troponin T assay is superior to its previous assay generation for prediction of 90-day clinical outcome in ischemic stroke. Clin Chem Lab Med 2012; 50: 2027-2029.
13 Scheitz JF, Mochmann HC, Erdur H. et al. Prognostic relevance of cardiac troponin T levels and their dynamic changes measured with a high-sensitivity assay in acute ischaemic stroke: analyses from the TRELAS cohort. Int J Cardiol 2014; 177: 886-893.
14 Ay H, Koroshetz WJ, Benner T. et al. Neuroanatomic correlates of stroke-related myocardial injury. Neurology 2006; 66: 1325-1329.
15 James P, Ellis CJ, Whitlock RM, McNeil AR, Henley J, Anderson NE. Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study. BMJ 2000; 320: 1502-1504.
16 Kerr G, Ray G, Wu O, Stott DJ, Langhorne P. Elevated troponin after stroke: a systematic review. Cerebrovasc Dis 2009; 28: 220-226.
17 Vafaie M, Biener M, Mueller M. et al. Analytically false or true positive elevations of high sensitivity cardiac troponin: a systematic approach. Heart 2014; 100: 508-514.
18 de Lemos JA. Increasingly sensitive assays for cardiac troponins: a review. JAMA 2013; 309: 2262-2269.
19 Twerenbold R, Jaffe A, Reichlin T, Reiter M, Mueller C. High-sensitive troponin T measurements: what do we gain and what are the challenges?. Eur Heart J 2012; 33: 579-586.
20 Laufs U, Hoppe UC, Rosenkranz S. et al. [Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society]. Nervenarzt 2010; 81: 444-462.
21 Alpert JS, Thygesen KA, White HD, Jaffe AS. Diagnostic and therapeutic implications of type 2 myocardial infarction: review and commentary. Am J Med 2014; 127: 105-108.
22 Scheitz JF, Mochmann HC, Nolte CH. et al. Troponin elevation in acute ischemic stroke (TRELAS) – protocol of a prospective observational trial. BMC Neurol 2011; 11: 98.
23 Samuels MA. The brain-heart connection. Circulation 2007; 116: 77-84.
24 Wittstein IS, Thiemann DR, Lima JA. et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005; 352: 539-548.
25 de Lemos JA, Drazner MH, Omland T. et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503-2512.
26 deFilippi CR, de Lemos JA, Christenson RH. et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010; 304: 2494-2502.
27 Hijazi Z, Siegbahn A, Andersson U. et al. Highsensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARIS-TOTLE) trial. Circulation 2014; 129: 625-634.
28 Scheitz JF, Erdur H, Haeusler KG. et al. Insular cortex lesions, cardiac troponin, and detection of previously unknown atrial fibrillation in acute ischemic stroke: insights from the troponin elevation in acute ischemic stroke study. Stroke 2015; 46: 1196-1201.
29 Zeller T, Tunstall-Pedoe H, Saarela O. et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J 2014; 35: 271-281.
30 Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med 2015; 373: 610-620.
31 Beatty AL, Ku IA, Bibbins-Domingo K. et al. Traditional risk factors versus biomarkers for prediction of secondary events in patients with stable coronary heart disease: From the Heart and Soul Study. J Am Heart Assoc 2015; 4: e001646.
32 McEvoy JW, Chen Y, Nambi V. et al. High-sensitivity cardiac troponin T and risk of hypertension. Circulation 2015; 132: 825-833.